Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS5385935 A
Type de publicationOctroi
Numéro de demandeUS 08/116,701
Date de publication31 janv. 1995
Date de dépôt7 sept. 1993
Date de priorité14 sept. 1992
État de paiement des fraisPayé
Autre référence de publicationCA2106172A1, CA2106172C, DE69310065D1, DE69310065T2, EP0588518A1, EP0588518B1
Numéro de publication08116701, 116701, US 5385935 A, US 5385935A, US-A-5385935, US5385935 A, US5385935A
InventeursYung-sheng Hsu, Hideo Tamai, Kinzo Ueda
Cessionnaire d'origineKissei Pharmaceutical Co., Ltd.
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Method for the inhibition of restenosis associated with coronary intervention
US 5385935 A
Résumé
This invention provides a method for treating patients to inhibit restenosis associated with coronary intervention. A 600 mg dosage of Tranilast for a treatment period of three consecutive months after coronary intervention lowers the incidence of restenosis, and reduces the degree of stenosis in patients.
Images(4)
Previous page
Next page
Revendications(8)
What is claimed is:
1. A method for the inhibition restenosis associated with coronary intervention in a human patient, which comprises administering to the patient 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof in a daily dose of about 300-1000 mg for a treatment period of at least three consecutive months after coronary intervention.
2. A method in accordance with claim 1 wherein the dosage is between about 300-600 mg of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or a pharmaceutically acceptable salt thereof.
3. A method in accordance with claim 1 wherein the treatment period is between about 3-6 consecutive months after coronary intervention.
4. A method in accordance with claim 1 wherein the dosage is administered orally.
5. A method in accordance with claim 1 wherein the dosage is administered parenterally.
6. A method in accordance with claim 1 wherein the coronary intervention is Percutaneous Transluminal Coronary Angioplasty.
7. A method in accordance with claim 1 wherein the coronary intervention is Direction Coronary Atherectomy.
8. A method in accordance with claim 1 wherein the coronary intervention is Stent.
Description
FIELD OF THE INVENTION The present invention relates to a method for the inhibition of restenosis associated with coronary intervention.

More particularly, the method comprises administrating to a human patient after coronary intervention an oral or parenteral dose of 2-(2,3-dimethoxycinnamoyl)aminobenzoic acid (Tranilast) represented by the following formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. ##STR1##

Illustrative of pharmaceutically acceptable salts are inorganic salts such as sodium or calcium salt, or organic salts formed with amines such as morpholine, piperidine, arginine, and the like.

As coronary intervention in the present invention, for example, Percutaneous Transluminal Coronary Angioplasty (PTCA), Direction Coronary Atherectomy and Stent can be included.

BACKGROUND OF THE INVENTION

1. Technical Field of the Invention

Coronary intervention is a surgical approach to the treatment of ischemic heart diseases such as angina pectoris and myocardial infarction. Coronary intervention technically involves mechanical revascularization of a stenosed lesion in a coronary artery by means of a balloon catheter, an atherectomy catheter and the like. As a consequence, coronary intervention often causes restenosis due to damaged intima cells.

Up to the present time, there has not been any effective drug for the treatment or prevention of restenosis associated with coronary intervention.

2. DESCRIPTION OF THE RELATED ART

Tranilast is sold commercially as a drug for the treatment of allergic diseases, e.g., allergic bronchitis, allergic asthma, atopic dermatitis, and the like, based on the activity exhibited by the drug for inhibiting release of chemical mediators [The Journal of Allergy and Clinical Immunology, Vol. 57, No. 5, pp. 396-407, (1976)].

Recently, in Biochemical Pharmacology, Vol.36, No. 4, pp. 469-474 (1987), it was reported that Tranilast inhibits fibroblast proliferation and collagen accumulation.

Further, it is noted of record that the authors of the present invention embodiments reported in Japanese College of Cardiology (1988) the treatment of patients subjected to PTCA surgery with Tranilast in a daily oral dose of 300 mg for 30 consecutive days after the PTCA surgery. The clinical data did not indicate any significant efficacy for preventing a restenosis effect associated with PTCA surgery.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a method for the prevention or treatment of restenosis associated with coronary intervention by administering 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid or pharmaceutically acceptable salt thereof to an adult patient after coronary intervention.

Other objects, features and advantages of the present invention will become apparent from the following description and examples.

DETAILED DESCRIPTION OF THE INVENTION

It is documented that restenosis associated with coronary intervention occurs within a period of about six months after coronary intervention. The clinical test data described in the Description Of The Related Art above were obtained over a test period of 30 consecutive days after the PTCA surgery. It was speculated by the present inventors that the lack of any significant efficacy for preventing a restenosis effect with Tranilast might be due to the relatively short 30 day duration of the drug treatment after PTCA surgery.

Further clinical testing of patients was conducted to determine if an extended period of Tranilast treatment might be effective for lowering the incidence of post-surgery restenosis associated with PTCA. It was found that Tranilast dosage of patients for a duration of at least about three months (i.e., a term of at least about 90 consecutive days of treatment) reduced the incidence of restenosis associated with the PTCA surgery.

In one clinical study, when patients were administered Tranilast in a daily oral dose of 600 mg for three consecutive months after PTCA surgery, the incidence of restenosis was less than about 20%.

The incidence of restenosis associated with PTCA surgery usually is about 40%, as reported in Percutaneous Transluminal Coronary Angioplasty, page 179 (1990). Thus, the present invention demonstrates that Tranilast dosage of patients after PTCA surgery is effective for reducing the incidence of restenosis during the treatment period. In patients in which the incidence of restenosis occurs when under Tranilast treatment, the mean degree of stenosis is minimized. The need for a second PTCA intervention is significantly reduced.

When Tranilast or a pharmaceutically acceptable salt thereof is employed therapeutically, it can be administered orally or parenterally in appropriate dosage forms, such as powder, granules, tablets, capsules, injectable solutions, and the like.

A Tranilast pharmaceutical composition can be formulated by admixing suitable carriers such as excipients, disintegrators, binders, brighteners, and the like, and preparing in accordance with conventional molding methods and dosage forms.

For example, a powder dosage form can be formulated by admixing Tranilast or a pharmaceutically acceptable salt thereof with suitable excipients, binders, brighteners, and the like.

Tablets can be formulated by admixing Tranilast or a pharmaceutically acceptable salt thereof with suitable excipients, disintegrators, binders, brighteners, and the like, and compressing the mixture with conventional molding equipment. The tablets also can be coated to provide film-coated tablets, sugar-coated tablets, enteric-coated tablets, and the like.

Capsules can be formulated by admixing Tranilast or a pharmaceutically acceptable salt thereof with suitable excipients, brighteners, and the like, and filling the mixture in capsules, or by forming granules containing Tranilast or a pharmaceutically acceptable salt thereof with conventional molding equipment, and filling the formed granules in capsules.

When a pharmaceutical composition of the present invention is employed therapeutically, the dosage of Tranilast or a pharmaceutically acceptable salt thereof as an active ingredient can be in a range between about 300-1000 mg. A preferred dosage is between about 300-600 mg per adult patient by oral administration on a daily basis for a treatment period of about 3-6 consecutive months after coronary intervention. The dosage and a term of administration are changed depending upon the weight and age and sex of the patient, the severity of the condition to be treated, and the like.

The present invention is further illustrated in more detail by way of the following Examples.

EXAMPLE I

This Example demonstrates the efficacy of the invention method for treatment of restenosis associated with PTCA surgery.

One hundred forty nine lesions with a partial occlusion, which underwent successful PTCA procedures with smooth dilation, were selected for this study. These lesions were divided into two groups, and both groups did not differ significantly with sex, distribution of coronary artery and ratio of lesions restenosed after PTCA; One group (49 lesions) received Tranilast in a daily dose of 600 mg (hereinafter identified as the R group), and the other group (100 lesions) did not receive Tranilast (hereinafter identified as the C group). In addition, all patients were also given calcium antagonists, nitrites and anti-platelets. These drugs were administered for 3 consecutive months after PTCA, and follow-up coronary angiography was performed in 3 months after PTCA.

The measurements were made in two projections using a direct caliper system, and all measurements (before and immediately after PTCA and at final follow-up) were made in the same projection for more accurate comparison.

Diameter stenosis was calculated as the mean of measurements, and restenosis was defined as a loss of at least 50% of the initial gain in luminal diameter accomplished by dilation.

A. The ratio of female-to-male, distribution of coronary vessel, and the ratio of lesions restenosed after PTCA were as follows:

(1) The ratio of female-to-male

R group: 18%; C group: 29%

(2) Distribution of coronary vessel

(R group and C group)

left anterior descending artery: left circumflex artery: right coronary artery =1:1:1

(3) The ratio of lesions restenosed after PTCA

R group: 49.0%; C group: 35.6%

B. The results of examination were as follows.

(1) The change of stenosis diameter

Pre-PTCA

R group: 68.4%.+-.12.3%;

C group: 71.1%.+-.11.5%, ns

Post-PTCA

R group: 14.8%.+-.11.6%;

C group: 18.5%.+-.11.0%, ns

There months after PTCA

R group: 25.8%.+-.18.2%;

C group: 41.2%.+-.26.8%, (p<0.001)

(2) The incidence of restenosis

R group: 12.2%; C group: 38.0% (p <0.01)

The comparative clinical data demonstrate the efficacy of 3 month Tranilast treatment for the prevention of restenosis in patients after PTCA surgery. The following comparative Example demonstrates that a one month Tranilast treatment is not effective for reducing restenosis in patients after PTCA surgery.

EXAMPLE II

This Example illustrates a one month treatment of patients with Tranilast which is not effective for reducing the incidence of restenosis associated with PTCA surgery.

Three hundred fifty two lesions with a partial occlusion, which underwent successful PTCA procedures with smooth dilation, were selected for this study. These lesions were divided into two groups, and both groups did not differ significantly with sex, age, number of diseased vessels, distribution of coronary artery and mean degree of stenosis (%) before PTCA; One group (100 lesions) received Tranilast in a daily dose of 300 mg for 30 consecutive months (hereinafter identified as the R' group), and the other group (252 lesions) did not receive Tranilast (hereinafter identified as the C' group). In addition, all patients were also given calcium antagonists, vasodilators and anti-platelets for 3 consecutive months after PTCA. Follow-up coronary angiography was performed in 3 months after PTCA.

The measurements were made in two projections using a direct caliper system, and all measurements (before and immediately after PTCA and at final follow-up) were made in the same projection for more accurate comparison.

Diameter stenosis was calculated as the mean of measurements, and restenosis was defined as a loss of at least 50% of the initial gain in luminal diameter accomplished by dilation.

The results were as follows:

(1) The change of stenosis diameter

Pre-PTCA

R' group: 86.1%; C' group: 78.7%, ns

Post-PTCA

R' group: 78.4%; C' group: 22.5%, ns

Three month after PTCA

R' group: 78.4%; C' group: 74.9%, ns

(2) The incidence of restenosis

R' group: 32.1%; C' group: 36.1%, ns

The one month treatment with a 300 mg dosage did not have a significant effect in reducing the incidence of restenosis in patients after PTCA surgery.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US3940422 *17 janv. 197424 févr. 1976Kissei Yakuhin Kogyo Kabushiki KaishaAromatic carboxylic amide derivatives
US4070484 *21 déc. 197624 janv. 1978Kissei Pharmaceutical Co., Ltd.Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
US4337270 *21 mai 198029 juin 1982Hisamitsu Pharmaceutical Co., Inc.Novel anthranilic acid derivatives
Citations hors brevets
Référence
1Garcia, Mesa, "New approach to the mechanism of antiasthmatic action of Tranilast" Allergol Immunopathol, vol. 18 issue (1). 1990.
2 *Garcia, Mesa, New approach to the mechanism of antiasthmatic action of Tranilast Allergol Immunopathol , vol. 18 issue (1). 1990.
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US5545569 *25 mai 199513 août 1996Neorx CorporationPrevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5595722 *7 juin 199521 janv. 1997Neorx CorporationMethod for identifying an agent which increases TGF-beta levels
US5599844 *15 sept. 19954 févr. 1997Neorx CorporationPrevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5824644 *3 juil. 199620 oct. 1998G. D. Searle & Co.Method of attenuating arterial stenosis
US5847007 *12 mai 19948 déc. 1998Neorx CorporationPrevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6019104 *30 déc. 19961 févr. 2000Kissei Pharmaceutical Co., Ltd.Method for the treatment or prevention of restenosis associated with coronary intervention
US6114383 *13 févr. 19985 sept. 2000Kissei Pharmaceutical Co., Ltd.Drugs inhibiting progress of pterygium and postoperative recurrence of the same
US617160923 oct. 19959 janv. 2001Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US63954947 juin 199528 mai 2002Neorx CorporationMethod to determine TGF-β
US640713912 févr. 199718 juin 2002Kissei Pharmaceutical Co., Ltd.Neovascularization inhibitor
US651500915 févr. 19954 févr. 2003Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US6552083 *7 juil. 200022 avr. 2003Kissei Pharmaceutical Co., Ltd.Agents inhibiting chronic rejection reactions after organ transplantation
US6652575 *14 déc. 200125 nov. 2003Scimed Life Systems, Inc.Stent with smooth ends
US6663881 *18 déc. 200116 déc. 2003Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US67675441 avr. 200227 juil. 2004Allergan, Inc.Methods for treating cardiovascular diseases with botulinum toxin
US704892728 juil. 200323 mai 2006Allergan, Inc.Botulinum neurotoxin eluting stent
US709455026 mars 200222 août 2006Neorx CorporationMethod to determine TGF-beta
US72233991 févr. 200629 mai 2007Allergan, Inc.Methods for treating restenosis with a botulinum neurotoxin
US747373830 sept. 20046 janv. 2009Johnson & Johnson Vision Care, Inc.Lactam polymer derivatives
US795613117 mars 20107 juin 2011Johnson & Johnson Vision Care, Inc.Lactam polymer derivatives
WO2000045810A1 *2 févr. 200010 août 2000Granett Jeffrey RMethod for the prevention or reduction of cardiovascular events associated with coronary intervention
WO2000045811A1 *2 févr. 200010 août 2000Granett Jeffrey RMethod for the prevention or reduction of cariovascular events associated with coronary intervention
WO2001062241A1 *22 févr. 200130 août 2001Danoff Theodore MMethod for the prevention or reduction of vascular access dysfunction
Classifications
Classification aux États-Unis514/535, 514/930
Classification internationaleA61P9/10, A61K31/19, A61K31/195, A61P43/00, A61P9/00
Classification coopérativeY10S514/93, A61K31/19
Classification européenneA61K31/19
Événements juridiques
DateCodeÉvénementDescription
24 avr. 2006FPAYFee payment
Year of fee payment: 12
19 juin 2002FPAYFee payment
Year of fee payment: 8
31 mars 1998FPAYFee payment
Year of fee payment: 4
15 août 1995CCCertificate of correction
7 sept. 1993ASAssignment
Owner name: KISSEI PHARMACEUTICAL CO., LTD., JAPAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMAI, HIDEO;UEDA, KINZO;HSU, YUNG-SHENG;REEL/FRAME:006693/0226
Effective date: 19930831